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ABSTRAK ABSTRACT
Tujuan: membandingkan kadar kreatinin dan cystatin C dengan
keparahan preeklampsia, serta menilai luaran neonatalnya.
Bahan dan Metode: Dilakukan pemeriksaan kreatinin dan
cystatin C, dan luaran neonatal pada 17 sampel kelompok normo-
tensi, 17 sampel preeklampsia ringan (PER) dan 17 sampel
preeklampsia berat (PEB). Analisa data dengan uji statistik anova
dan dengan uji t perbedaan antar 2 proporsi.
Hasil: Kadar rerata kreatinin pada kelompok Normotensi, PER,
PEB yaitu 0,56 mg/dL, 0,67 mg/dL, dan 0,75 mg/dL, p=0,138;
Sedangkan pada cystatin C yaitu 0,82 mg/L, 1,03 mg/L, dan 1,32
mg/L, p=0,000. Tidak ditemukan luaran neonatal yang buruk pada
kelompok normotensi. Pada kelompok PER didapatkan 1 bayi
lahir preterm dan 1 bayi IUFD, sedangkan pada kelompok PEB
didapatkan 3 bayi lahir preterm, 1 bayi IUFD, dan 1 bayi IUGR.
Simpulan: kadar cystatin C meningkat secara bermakna seiring
dengan peningkatan keparahan preeklampsia, sedangkan kreatinin
tidak meningkat secara bermakna. Cystatin C merupakan penanda
gangguan fungsi ginjal pada pasien preeklampsia yang lebih baik
dibandingkan kreatinin. Terdapat peningkatan luaran neonatus
yang buruk pada kelompok preeklampsia.
Kata Kunci: kreatinin, cystatin C, preeklampsia, luaran neonatal
Objectives: to compare the levels of creatinine and cystatin C
with the severity of preeclampsia, and assess neonatal outcomes.
Materials and Methods: Creatinine, cystatin C, and neonatal
outcomes were assesed in 17 normotensive samples, 17 samples
of mild preeclampsia and 17 samples of severe preeclampsia.
Analysis of data with statistical tests of ANOVA and t test
differences between 2 proportions.
Results: The mean levels of creatinine in the normotensive group,
mild preeclampsia, severe preeclampsia are 0.56 mg/dL, 0.67 mg/
dL, and 0.75 mg/dL, p=0.138; While on cystatin C are 0.82 mg/L,
1.03 mg/L and 1.32 mg/L, p=0.000. The adverse neonatal out-
come wasn’t found in the normotensive group. In mild pre-
eclampsia obtained 1 preterm birth and 1 intrauterine fetal death
(IUFD), whereas in severe preeclampsia obtained 3 babies born
preterm, 1 IUFD, and 1 intrauterine growth restriction (IUGR).
Conclusion: levels of cystatin C was increased significantly in
line with increased severity of preeclampsia, whereas creatinine
was not increased significantly. Cystatin C is better than crea-
tinine as a marker of renal dysfunction in preeclampsia patients.
There was an increase in adverse neonatal outcomes in the group
of preeclampsia.
Keywords: creatinine, cystatin C, preeclampsia, neonatal
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INTRODUCTION
Preeclampsia is a pregnancy pathology which causes
health problems to mothers and their unborn babies
because of its incidence and mortality both in the world
and in Indonesia. In the whole world, pre-eclampsia has
caused 50,000 maternal deaths and 900,000 perinatal
deaths annually. The incidence of preeclampsia in
pregnancy is 5-10% and becomes one of the three main
causes of maternal mortality after bleeding and infect-
ion. Indonesia's maternal mortality remains dominated
by three major causes of death which are hemorrhage,
hypertension in pregnancy, and infection. The propor-
tion among those three causes of maternal death has
changed, as bleeding and infection tend to decrease
while hypertension in pregnancy proportion is increas-
ing.1-3 Preeclampsia is a disorder of various organ
systems which is characterized by hypertension and
proteinuria after 20 weeks of pregnancy. Preeclampsia
is originated from defects of trophoblast invasion and
the spiral arteries remodeling that then lead to placental
ischemia. These placental ischemia causes the placenta
to produce soluble factors that cause endothelial dys-
function. The clinical features of preeclampsia causes
kidney, as the main target organ, to experience glomer-
ular endotheliosis that causes a decrease in glomerular
filtration rate.4,5
Preeclampsia and eclampsia are 75% of the causes of
acute renal failure in pregnancy. Thus, impaired kidney
function is a component that should be a major concern
in preeclampsia. Renal function monitoring is necessary
so that earlier treatment can be implemented to prevent
further kidney damage. Creatinine and cystatin C is a
marker of kidney function that can be used in pre-
eclampsia. Exchange of low molecular weight sub-
stances such as creatinine and cystatin C occurred in the
kidney. Creatinine is a biomarker of kidney function
that is most widely used.6-8
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Creatinine is the anhydride form of creatine anhydride
produced as the end product of phospho-creatine
decomposition. Creatinine is eliminated by renal glome-
rular filtration and a little amount of it sis secreted by
renal tubular. Creatinine excretion depends on skeletal
muscle mass, age, gender and diet. Serum creatinine
level increases in patients with renal impairment,
especially with a significant reduction in glomerular fil-
tration.4,9,10
Serum creatinine is limited in assessing the glomerular
filtration rate, because a decrease in glomerular filtra-
tion rate of up to 50% can be without an increased
serum creatinine concentration. The average level of
creatinine in preeclampsia does not always rise above
the reference limit which is appropriate for normal
pregnancy, and this reduces the usefulness of these pa-
rameters to monitor the occurrence of renal dysfunc-tion
in patients with preeclampsia. Creatinine is unable to
detect a decrease in glomerular filtration rate in the
early stages of kidney dysfunction, therefore it is impor-
tant to use new biomarkers such as cystatin C. Serum
cystatin C is an endogenous marker of renal function.
Cystatin C is synthesized by all nucleated cells and
excreted from the body's circulation exclusively through
glomerular filtration. From the above explan-ation, the
serum cystatin C has superior diagnostic accuracy as a
marker of glomerular endoteliosis or renal involvement
in preeclampsia compared to creatin-ine.4,11,12
Studies conducted Franceschini et al (2008) and Mona
Faraq et al (2011) found that cystatin C levels rise
higher in patients with preeclampsia compared than in
normotensive pregnancy.Helena Strevens et al (2002)
compared the levels of cystatin C, creatinine and uric
acid. Cystatin C has superior diagnostic accuracy for
preeclampsia compared with serum uric acid or creati-
nine.11-13
Incidence of perinatal morbidity and mortality is rising
in pregnancy with preeclampsia, and this is mainly due
to preterm labor and uteroplacental insufficiency, which
results in decreased blood flow to the fetus. Prematurity,
fetal growth retardation (IUGR), and fetal death (IUFD)
are neonatal complications that should be well-anti-
cipated in patients with preeclampsia.14,15
Currently there are still few studies of comparative
levels of creatinine and cystatin C in patients with pre-
eclampsia and how the neonatal outcomes are, whereas
impaired renal function is an important compo-nent in
the pathophysiology of preeclampsia. Close monitoring
of renal function is essential to ensure on time delivery
before the onset of severe kidney damage that increases
neonatal morbidity and maternal mortal-ity.7,16
MATERIALS AND METHODS
This research is a cross sectional analytic approach to
assess the comparative levels of creatinine and cystatin
C with the severity of preeclampsia and neonatal out-
comes in patients with preeclampsia. The population of
this study is the third trimester pregnant women in
maternity wards Prof Dr RD Kandou Hospital, Manado
and its networking hospitals. Sample collection was
done by consecutive sampling. The samples consisted of
three groups, as follows: 17 normotensive women, 17
women with mild preeclampsia, and 17 women with
severe preeclampsia who meet the inclusion and
exclusion criteria.
The inclusion criterias are the third trimester pregnant
women with single fetus and willing to participate in the
study. While the exclusion criterias are: pregnant
women with diabetes mellitus, chronic hypertension,
kidney disease, infections, and twin fetus. The research
uses subjest’s blood samples, then examines the levels
of creatinine and cystatin C of those samples in the
Prodia laboratory Manado.
Data analysis was done using ANOVA statistical test to
compare the levels of creatinine and cystatin C with the
severity of preeclampsia. The data obtained were pro-
cessed using the software program Statistical Product
and Service Solution (SPSS) for Windows version 22.
The t-test difference between 2 proportions is used to
look for fetal outcomes in patients with preeclampsia.
The data obtained are then processed with Stata 10
statistical program.
RESULTS AND DISCUSSION
A research on the population of aterm pregnant women
in Prof. Kandou Hospital and the networking hospitals
from August to November 2015 has been done with a
total sample of 51 samples consisting of 17 normoten-
sive samples, 17 mild preeclampsia samples, and 17
severe preeclampsia samples. Characteristics of the
sample in this study can be seen in Table 1.
This research obtained 0.8 mg/dL as the highest levels
of creatinine for normotensive pregnant woman and 0.4
mg/dL as the lowest. In the group of mild preeclampsia,
the highest level of creatinine was 1.1 mg/dL and the
lowest level was 0.4 mg/dL. In severe preeclampsia
group, the highest level of creatinine was 1.1 mg/dL and
the lowest level was 0.5 mg/dL (Figure 1). ANOVA
statistical test showed that there was no significant
difference in creatinine levels among those three groups
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(normotensive, mild preeclampsia and severe pre-
eclampsia), with a value of p=0.138 (Table 2).
This research obtained 1.11 mg/L as the highest levels
of cystatin C for normotensive pregnant women and the
0.66 mg/L as the lowest level. In the group of mild
preeclampsia, the highest levels of cystatin C was 1.25
mg/L and the lowest level was 0.83 mg/L. At the severe
preeclampsia group, the highest levels of cystatin C
concentration was 1.58 mg/L and the lowest level was
0.98 mg/L. ANOVA statistical test showed that p=0.000
which shows that the level of cystatin C in normo-
tensive is different with in the mild preeclampsia and
the severe preeclampsia groups.
In this study, ANOVA test on creatinine and cystatin C
showed that cystatin C increased significantly along
with an increase in the severity of preeclampsia, while
creatinine did not increase significantly.
Table 1. Characteristics of research subjects
Characteristics
Normotensive MPE SPE
N % N % N %
Maternal age
≤ 20 years 4 23.5 - - 2 11.8
21-35 years 10 58.8 12 70.6 9 52.9
≥ 35 years 3 17.6 5 29.4 6 35.3
Parity
primigravida 7 41.2 4 23.5 6 35.3
multigravida 10 58.8 13 76.5 11 64.7
Work
Housewives 13 76.5 14 82.4 15 88.2
Private
section 3 17.6 2 11.8 - -
Students - - - - 1 5.9
Government
employees - - 1 5.9 1 5.9
Farmer 1 5.9 - - - -
Tribe
Minahasa 15 88.2 15 88.2 16 94.1
Java 2 11.8 2 11.8 0 -
Gorontalo - - - - 1 5.9
Number of
Marriages
1 17 100 17 100 15 88.2
˃ 1 - - - - 2 11.8
Table 2. Statistical analysis of creatinine levels
Serum creatinine
Levels
(mg/dL)
Mean
(mg/dL) SD P value
Normotensive 0.40- 0.80 0:56 0152 0.138
Mild
preeclampsia 0.40–1.10 0.67 0180
Severe
preeclampsia 0.50–1.10 0.75 0197
Figure 1. Creatinine levels in patients with normotensive,
mild preeclampsia, severe preeclampsia
Figure 2. Cystatin C levels in patients with normotensive, mild
preeclampsia, and severe preeclampsia
Table 3. Statistical analysis of cystatin c levels
Fetal outcomes in this study showed that there was no
bad fetal outcome in the normotensive group. In mild
preeclampsia group, the result showed one baby was
born preterm and 1 IUFD. In severe preeclampsia
group, the result showed three babies born preterm, 1
IUGR, and 1 IUFD. The results of T test differences
between 2 proportions by using a statistical program
Stata 10 were (Table 4): There were no significant
differences in the proportion of preterm infants between
the MPE and SPE group → p=0.287 (the proportions
are 1/17 and 3/17). There were no significant differen-
ces in the proportion of IUFD between the MPE and
SPE group → p=1.000 (the proportions are 1/17 and
1/17).
In this study the characteristics of the samples assessed
were maternal age, parity, employment, marriage, and
Cystatin C
Levels
(mg/dL)
Mean
(mg/dL) SD
P
value
Normotensive 0.66 - 1.11 0.82 0124 0000
Mild
preeclampsia 0.83 – 1.25 1.03 0121
Severe
preeclampsia 0.98 – 1.58 1.32 0168
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the tribe. In table 1 we can see the comparison of
sample characteristics in each blood pressure category,
such as normotensive, mild preeclampsia and severe
preeclampsia. The distribution of study subjects accord-
ing to age group was 15 to 42 years. The highest
percentage of the age group was at 21-34 years old, of
the parity was the multiparous pregnant women, of the
tribe was the Minahasa tribe.
Table 4. Relationship between neonatal outcomes with
preeclampsia
Neonatal
outcomes
Normotensive MPE SPE
N % N % N %
Preterm - - 1 1/17 3 3/17
IUGR - - - - 1 1/17
IUFD - - 1 1/17 1 1/17
The creatinine’s average levels in this study were not
significantly different between normotensive pregnancy
group, mild preeclampsia and severe preeclampsia,
which were 0.56 mg/dL, 0.67 mg/dL, and 0.75 mg/dL,
with a value of p=0.138. Therefore, it can be concluded
that the creatinine levels did not increase significantly
along with the severity of preeclampsia. These creatini-
ne results were different compared to the cystatin C
results. Serum cystatin C level between normotensive
pregnancy group with mild preeclampsia and with
severe preeclampsia, were not significantly different.
The results were 0.82 mg/l, 1.03 mg/L and 1.32 mg/L,
with p=0,000. Therefore, with ANOVA test towards
creatinine and cystatin C, it can be concluded cystatin C
level will increase significantly along with an increase
in the severity of preeclampsia, whereas creatinine will
not increase significantly.
This research supports the research conducted by Shalvi
Sharma et al (2014) who obtained serum cystatin C is
more superior as a marker of renal dysfunction com-
pared to creatinine in patients with preeclamp-
sia. Cystatin C concentration was significantly higher in
patients with preeclampsia (1.31±0.4 mg/L) compared
to normotensive pregnant women (0.96±0.2 mg/L), with
p <0.001. In contrary, creatinine concentration was not
significantly increased in patients with preeclampsia
(0.71±0.09 mg/dL) compared to normotensive pregnant
women (0.7±0.08 mg/dL), with p=0.907. Another
research conducted by Kurnia et al (2014), compared 19
cases of severe preeclampsia and 25 cases of normal
pregnancy, found a significantly different cystatin C
levels in severe preeclampsia compared with normal
pregnancy. The mean levels of serum cystatin C in
severe preeclampsia was 1.16±0.31 mg/L and in the
normotensive woman was 0.92±0.16 mg/L. (17,18)
A study conducted by Sumithra et al (2013) also obtain
similar results with our study, in which the cystatin C
increased significantly in preeclampsia patients, while
creatinine remained within normal limits. The average
level of creatinine in the preeclamptic group was
0.61±0.17 mg/dL and in the control group was 0.47±
0.08 mg/dL. The average levels of cystatin C in
preeclampsia group was 1.29±0.4 mg/L and in the
control group was 0.13±0.77 mg/L. There is no signify-
cant increase of creatinine in the preeclampsia group.4
Creatinine is a biomarker that has been used extensively
as a marker of kidney function but is less sensitive in
the early stages of kidney dysfunction. In the oher hand,
Cystatin C is very sensitive in assessing changes in
glomerular filtration rate on the early stages of renal
impairment. Furthermore, unlike creatinine, cystatin C
was not significantly affected by diet, infections, liver
function, malignancy, muscle mass and fat in evaluating
glomerular filtration rate, so that cystatin C can be a
better screening test for early detection of renal
dysfunction in patients with preeclampsia, compared to
creatinine.4,6,12
The increased mean of cystatin C levels in patients with
preeclampsia, which was due to renal morphological
changes characterized by endotheliosis, will inhibit
glomerular filtration, resulting in decreased rate of glo-
merular fitration. Cystatin C which has a small mole-
cular weight, freely goes through the glomerular mem-
brane. Unlike creatinine, cystatin C is not secreted by
the tubules but fully filtered by the glomerulus then
resorbed and catabolized by the kidney tubules. Thus,
cystatin C levels can be highly sensitive in depicting a
decrease in glomerular filtration rate.17,18
Creatinine levels increased in patients with impaired
renal function with severely decreased glomerular
filtration rate, so normal serum creatinine cannot
exclude an impaired renal function condition. Creatinine
is unable to detect a decrease in glomerular filtration
rate in the early stages of kidney dysfunction, therefore
it is important to use new biomarkers such as Cystatin C
since it has a superior diagnostic accuracy in preeclamp-
sia compared to creatinine.4,13,18
A study of renal biopsy performed by Strevens et al
(2003), found that cystatin C levels were correlated with
the severity of renal structural changes (glomerular
endoteliosis) that are typical in patients with pre-
eclampsia. Research by Roberto Costa et al (2015),
stated that there was a link between serum cystatin C
levels with proteinuria levels. Patients with severe
proteinuria have higher cystatin C levels compared to
patients with mild proteinuria. Glomerular cell damage
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results in increased permeability of the basement
membrane, causing leaks that leads to protein-
uria. Cystatin C is a marker of kidney function that can
be relied upon in assessing the severity of glomerular
cell damage. The declining of kidney function in
preeclampsia needs to be assessed so that the delivery
will be arranged in the right time before the onset of
severe renal impairment.4,10,17,19
In this study, there is an increase in bad neonatal
outcomes in preeclampsia group which is not found in
the normotensive group. The mild preeclampsia group
got one baby born preterm and 1 IUFD. In severe
preeclampsia group, there were three babies born
preterm, 1 IUFD, and 1 IUGR. The T test differences
between 2 proportions using Stata 10 statistical program
showed that there are no significant differences of
preterm infants and IUFD proportion between mild
preeclampsia and severe preeclampsia groups,
with p=0.287 and p=1.000.
The increasing incidence of perinatal morbidity and
mortality in pregnancy with preeclampsia, is mainly due
to preterm labor and uteroplacental insufficiency which
result in decreased blood flow (oxygen supply and
nutrients) to the fetus. Prematurity, growth retardation
and fetal mortality are neonatal complications that
should be well anticipated and dealt in patients with
preeclampsia.14,15
A cohort study done by Young et al, found that the
relative risk of neonatal death rate was at 34-42 weeks
gestational age group, using 40 weeks as the refer-
ence. Researchers showed the relative risk of neonatal
mortality decreased with the increasing gestational
age. In particular, the infant mortality rate of babies bein
born in gestational ages of 34, 35, and 36 weeks were
respectively 12.5; 8.7; and 6.3 times higher, compared
to aterm pregnancy (40 weeks) as a control.20
In the past, epidemiological research and patient care
guidelines, suggested 34 weeks of pregnancy as fetal
maturity age. Babies born between 34 and 36 weeks of
pregnancy were termed as "near term" baby and
believed to be at low risk for significant morbidity. This
causes relatively lack of concern about the con-
sequences of neonatal birth above 34 weeks gesta-
tion. However, later on, literatures indicated that
extendedd premature babies (≥ 34 weeks) have a greater
risk for a number of complications, especially respira-
tory problems. Several studies have shown that
premature babies have an increased risk of further
occurrence of respiratory distress syndrome (RDS),
transient tachypnea of the newborn (TTN), persistent
pulmonary hypertension (PPH) and respiratory failure
compared with term infants.14
Preeclampsia is a significant risk factor for the occur-
rence of intrauterine fetal death, with an estimated fetal
mortality rate of 21 per 1000. In severe preeclampsia the
risk of fetal death should be considered beyond the
benefits of continuing pregnancy. However, in mild
preeclampsia cases, the risk of fetal death is less than
50% of severe preeclampsia. Considering fewer risks of
intrauterine fetal death occurence in mild preeclampsia,
the childbirth could be delayed until 37 weeks for
intrauterine fetal maturation purposes.14
Growth is a marker of fetal well-being. Pregnancies
with intrauterine growth restrict-ion (IUGR) were
associated with increased perinatal mortality. In pre-
eclampsia, decreased uteroplacental blood flow and
ischemia are significant risk factors for IUGR and the
most common cause of IUGR in non-anomaly infants.
Body weight below the 10th percentile significantly
increase the risk of neonatal mortality.
Therefore, infants weighing 1,250 grams at 38-40 weeks
gesta-tional age had significantly greater risk of death
compared with 32 weeks gestational age infants with the
same body weight. Babies born from pregnancy with
severe preeclampsia have 12% lower birth weight than
expected, while the pregnancy with mild preeclampsia
showed no difference in the birth weight compared to a
normal pregnancy. This is consistent with the results of
our study which did not obtain IUGR in mild
preeclampsia group.14
CONCLUSION
From this study we found that cystatin C level will
increase significantly along with an increase in the
severity of preeclampsia, while creatinine will not
increase significantly. Cystatin C is a better marker of
renal dysfunction in patients with preeclampsia compar-
ed to creatinine. Preeclampsia group of mothers will
have worse neonatal outcomes compared to the normo-
tensive group. The bad outcomes were: prematurity,
IUGR, and IUFD.
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